Transient Ischemia without Thrombolytic DRG Reimbursement

Summary & Overview

Transient Ischemia without Thrombolytic: Inpatient Reimbursement Overview

DRG 069 addresses inpatient admissions for transient ischemia without thrombolytic therapy, focusing on short-stay medical management and observation for neurologic symptoms. It matters for inpatient reimbursement because proper diagnosis and coding determine payment under the prospective payment system and differentiate resource use from other cerebrovascular Diagnosis-Related Group categories.

Transient Ischemia without ThrombolyticDRG Transient Ischemia without ThrombolyticDRG 069Diagnosis-Related GroupInpatient ReimbursementMedicareNeurologyStroke EvaluationCerebrovascularObservation

DRG 069 Overview

DRG 069 covers inpatient encounters for transient ischemia without use of thrombolytic therapy, typically including transient ischemic attack presentations managed medically and observed for neurologic stability. This Diagnosis-Related Group groups cases with similar resource use and clinical severity for prospective payment under Medicare, influencing hospital reimbursement, length of stay expectations, and billing considerations. Accurate coding of diagnoses and comorbid conditions determines assignment to this Diagnosis-Related Group and affects payment relative to other cerebrovascular Diagnostic-Related Group categories.

National Payment Rates

Across commercial payers the observed rate range for DRG 069 spans roughly $5K to $27K, with the widest spread between the minimum and maximum values seen in Anthem data. Refer to the payer table and the accompanying chart below for payer-specific percentiles and distributions. Cigna, Aetna, Anthem, and BCBS show notable variation around their medians.

Mean Rates by Payer — National — DRG 069

The CMS 2023 data are national Medicare fee-for-service inpatient payment figures published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 069. These values summarize national Medicare payment experience for the period reported.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s DRG 069 mean reimbursements range from $12K to $19K across reported payers, with Cigna paying the most and BCBS and Anthem the least. Cigna’s mean ($19K) notably exceeds the national Cigna mean, while BCBS and Anthem sit at a lower, tightly clustered $12K. See the table and chart below for payer-level detail.

Key Insights for Alaska

Highest payer: Cigna (mean $19K) is the highest payer among listed payers; lowest payers: BCBS and Anthem (both mean $12K).
Alaska’s payer means range ($12K–$19K) is compressed but Cigna’s mean sits above the national Cigna mean (~$13K), representing a meaningful upward deviation for that payer.
BCBS and Anthem means ($12K) align with or exceed some national medians, indicating limited downside risk compared with national variability.

Clinical Trials

Trials of early diagnostic and risk stratification strategies for transient ischemic attacks (TIAs) focus on rapid identification of patients at highest short-term stroke risk using combinations of clinical scores, neuroimaging protocols, and blood biomarkers. These studies enroll acute-care patients presenting to emergency departments or observation units within 24–72 hours of transient neurologic symptoms and evaluate which diagnostic algorithms most accurately predict subsequent stroke or need for inpatient admission. Findings are directly relevant to providers and payers because better early risk stratification can reduce unnecessary admissions, target scarce resources (advanced imaging, neurology consultation), and prevent costly readmissions or downstream stroke care.
Comparative effectiveness studies evaluate secondary prevention strategies initiated during the inpatient stay or observation period after a TIA, comparing different antithrombotic approaches, blood pressure and lipid management intensities, or combinations of interventions in diverse patient subgroups (eg, atrial fibrillation vs noncardioembolic TIAs). These trials typically follow patients for months to a year to measure recurrent stroke, major bleeding, functional outcomes, and healthcare utilization. Payers and hospitals benefit from evidence showing which inpatient-initiated prevention pathways most effectively reduce recurrence and long-term costs while balancing safety risks for the heterogeneous TIA population captured in this DRG.
Post-discharge care coordination and health-services research examines models of transitional care for TIA patients — for example, fast-track outpatient TIA clinics, telehealth follow-up, medication adherence interventions, and social determinant screening — assessing their impact on 30- and 90-day readmissions, outpatient utilization, and patient-reported outcomes. These studies enroll patients discharged from emergency departments or short inpatient stays and measure pragmatic outcomes important to systems: timeliness of specialist follow-up, adherence to guideline-recommended testing and therapies, and preventable utilization. Results inform providers and payers about scalable approaches to reduce avoidable readmissions and improve value-based care for the TIA population represented by this DRG.

Related Codes

038-EXTRACRANIAL-PROCEDURES-WITH-CC

Extracranial Procedures with CC: Inpatient Reimbursement Overview

035-CAROTID-ARTERY-STENT-PROCEDURES-WITH-CC

Carotid Artery Stent Procedures with CC: Inpatient Reimbursement Overview

073-CRANIAL-AND-PERIPHERAL-NERVE-DISORDERS-WITH-MCC

Cranial and Peripheral Nerve Disorders with MCC: Inpatient Reimbursement Overview

067-PRECEREBRAL-OCCLUSION-WITHOUT-INFARCTION-WITH-MCC

Precerebral Occlusion without Infarction with MCC: Inpatient Reimbursement Overview

034-CAROTID-ARTERY-STENT-PROCEDURES-WITH-MCC

Carotid Artery Stent Procedures with MCC: Inpatient Reimbursement Overview

020-INTRACRANIAL-VASCULAR-PROCEDURES-WITH-PRINCIPAL-DIAGNOSIS-HEMORRHAGE-WITH-MCC

Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage with MCC: Inpatient Reimbursement Overview

031-VENTRICULAR-SHUNT-PROCEDURES-WITH-MCC

Ventricular Shunt Procedures with MCC: Inpatient Reimbursement Overview

083-TRAUMATIC-STUPOR-AND-COMA-1-HOUR-WITH-CC

Traumatic Stupor and Coma >1 Hour with CC: Inpatient Reimbursement Overview

071-OTHER-CEREBROVASCULAR-DISORDERS-WITH-CC

Other Cerebrovascular Disorders with CC: Inpatient Reimbursement Overview

074-CRANIAL-AND-PERIPHERAL-NERVE-DISORDERS-WITHOUT-MCC

Cranial and Peripheral Nerve Disorders without MCC: Inpatient Reimbursement Overview

Showing 1–10 of 71

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$7.4K	$47K	$5.6K	28K

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 069

Key Insights for Alaska

Highest payer: Cigna (mean $19K) is the highest payer among listed payers; lowest payers: BCBS and Anthem (both mean $12K).
Alaska’s payer means range ($12K–$19K) is compressed but Cigna’s mean sits above the national Cigna mean (~$13K), representing a meaningful upward deviation for that payer.
BCBS and Anthem means ($12K) align with or exceed some national medians, indicating limited downside risk compared with national variability.

Clinical Trials

Trials of early diagnostic and risk stratification strategies for transient ischemic attacks (TIAs) focus on rapid identification of patients at highest short-term stroke risk using combinations of clinical scores, neuroimaging protocols, and blood biomarkers. These studies enroll acute-care patients presenting to emergency departments or observation units within 24–72 hours of transient neurologic symptoms and evaluate which diagnostic algorithms most accurately predict subsequent stroke or need for inpatient admission. Findings are directly relevant to providers and payers because better early risk stratification can reduce unnecessary admissions, target scarce resources (advanced imaging, neurology consultation), and prevent costly readmissions or downstream stroke care.
Comparative effectiveness studies evaluate secondary prevention strategies initiated during the inpatient stay or observation period after a TIA, comparing different antithrombotic approaches, blood pressure and lipid management intensities, or combinations of interventions in diverse patient subgroups (eg, atrial fibrillation vs noncardioembolic TIAs). These trials typically follow patients for months to a year to measure recurrent stroke, major bleeding, functional outcomes, and healthcare utilization. Payers and hospitals benefit from evidence showing which inpatient-initiated prevention pathways most effectively reduce recurrence and long-term costs while balancing safety risks for the heterogeneous TIA population captured in this DRG.
Post-discharge care coordination and health-services research examines models of transitional care for TIA patients — for example, fast-track outpatient TIA clinics, telehealth follow-up, medication adherence interventions, and social determinant screening — assessing their impact on 30- and 90-day readmissions, outpatient utilization, and patient-reported outcomes. These studies enroll patients discharged from emergency departments or short inpatient stays and measure pragmatic outcomes important to systems: timeliness of specialist follow-up, adherence to guideline-recommended testing and therapies, and preventable utilization. Results inform providers and payers about scalable approaches to reduce avoidable readmissions and improve value-based care for the TIA population represented by this DRG.